Shares of Johnson & Johnson (NYSE:JNJ) have earned an average recommendation of “Hold” from the twenty-two brokerages that are presently covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and eleven have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $145.64.

JNJ has been the topic of several analyst reports. Cowen reaffirmed an “outperform” rating and set a $155.00 price target (up from $147.00) on shares of Johnson & Johnson in a research report on Wednesday, October 18th. Jefferies Group upped their price target on shares of Johnson & Johnson from $157.00 to $160.00 and gave the stock a “buy” rating in a research report on Monday, October 16th. Zacks Investment Research raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Wednesday, October 4th. Credit Suisse Group set a $154.00 price target on shares of Johnson & Johnson and gave the stock an “outperform” rating in a research report on Thursday, October 19th. Finally, Barclays upped their price target on shares of Johnson & Johnson from $140.00 to $148.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 18th.

Several large investors have recently added to or reduced their stakes in JNJ. Harding Loevner LP acquired a new position in shares of Johnson & Johnson in the second quarter valued at about $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its stake in shares of Johnson & Johnson by 29.9% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after acquiring an additional 200 shares in the last quarter. Lenox Wealth Advisors Inc. grew its stake in shares of Johnson & Johnson by 0.6% in the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after acquiring an additional 5 shares in the last quarter. IHT Wealth Management LLC grew its stake in shares of Johnson & Johnson by 46.4% in the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock valued at $122,000 after acquiring an additional 3,467 shares in the last quarter. Finally, Mountain Capital Investment Advisors Inc acquired a new position in shares of Johnson & Johnson in the second quarter valued at about $124,000. Hedge funds and other institutional investors own 65.71% of the company’s stock.

Shares of Johnson & Johnson (JNJ) opened at $147.36 on Friday. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36. The company has a market cap of $395,890.00, a price-to-earnings ratio of 25.58, a PEG ratio of 2.75 and a beta of 0.80. Johnson & Johnson has a 1 year low of $110.76 and a 1 year high of $148.32.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 19.16% and a return on equity of 20.70%. The firm had revenue of $19.65 billion for the quarter, compared to analyst estimates of $19.29 billion. During the same period in the prior year, the firm posted $1.68 earnings per share. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. research analysts forecast that Johnson & Johnson will post 7.28 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 13th. Shareholders of record on Tuesday, February 27th will be issued a $0.84 dividend. The ex-dividend date of this dividend is Monday, February 26th. This represents a $3.36 annualized dividend and a dividend yield of 2.28%. Johnson & Johnson’s dividend payout ratio is currently 58.33%.

TRADEMARK VIOLATION WARNING: This report was first reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2018/01/20/johnson-johnson-jnj-receives-average-recommendation-of-hold-from-analysts.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.